EP4125837A4 - Verwendung von bupropion- und dextromethorphan-kombinationen zur behandlung von neurologischen erkrankungen - Google Patents

Verwendung von bupropion- und dextromethorphan-kombinationen zur behandlung von neurologischen erkrankungen Download PDF

Info

Publication number
EP4125837A4
EP4125837A4 EP21779322.3A EP21779322A EP4125837A4 EP 4125837 A4 EP4125837 A4 EP 4125837A4 EP 21779322 A EP21779322 A EP 21779322A EP 4125837 A4 EP4125837 A4 EP 4125837A4
Authority
EP
European Patent Office
Prior art keywords
dextromethorphane
bupropion
combinations
neurological diseases
treat neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21779322.3A
Other languages
English (en)
French (fr)
Other versions
EP4125837A1 (de
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antecip Bioventures II LLC
Original Assignee
Antecip Bioventures II LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/894,713 external-priority patent/US10898453B2/en
Application filed by Antecip Bioventures II LLC filed Critical Antecip Bioventures II LLC
Publication of EP4125837A1 publication Critical patent/EP4125837A1/de
Publication of EP4125837A4 publication Critical patent/EP4125837A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP21779322.3A 2020-03-30 2021-03-29 Verwendung von bupropion- und dextromethorphan-kombinationen zur behandlung von neurologischen erkrankungen Pending EP4125837A4 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063002132P 2020-03-30 2020-03-30
US202063016178P 2020-04-27 2020-04-27
US202063032517P 2020-05-29 2020-05-29
US202063032567P 2020-05-30 2020-05-30
US16/894,713 US10898453B2 (en) 2013-11-05 2020-06-05 Bupropion as a modulator of drug activity
PCT/US2021/024718 WO2021202419A1 (en) 2020-03-30 2021-03-29 Use of bupropion and dextromethorphan combinations for treating neurological disorders

Publications (2)

Publication Number Publication Date
EP4125837A1 EP4125837A1 (de) 2023-02-08
EP4125837A4 true EP4125837A4 (de) 2024-03-20

Family

ID=77930161

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21779322.3A Pending EP4125837A4 (de) 2020-03-30 2021-03-29 Verwendung von bupropion- und dextromethorphan-kombinationen zur behandlung von neurologischen erkrankungen

Country Status (6)

Country Link
EP (1) EP4125837A4 (de)
JP (2) JP7637150B2 (de)
KR (1) KR20220161414A (de)
CN (1) CN115697314A (de)
CA (1) CA3179048A1 (de)
WO (1) WO2021202419A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
JP2023553393A (ja) 2020-12-01 2023-12-21 アンテシップ バイオベンチャーズ トゥー エルエルシー うつ病患者の自殺リスク低減のためのブプロピオンおよびデキストロメトルファン
WO2023004064A1 (en) * 2021-07-21 2023-01-26 Antecip Bioventures Ii Llc Treatment of depression
KR20250011185A (ko) * 2022-05-17 2025-01-21 안테씨프 바이오벤쳐스 투 엘엘씨 우울증의 치료
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
KR20250114110A (ko) * 2022-11-28 2025-07-28 안테씨프 바이오벤쳐스 투 엘엘씨 약물 활성의 조절제로서의 부프로피온

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US20200215059A1 (en) * 2013-11-05 2020-07-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20210052521A1 (en) * 2013-11-05 2021-02-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20210077428A1 (en) * 2013-11-05 2021-03-18 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113750099A (zh) * 2013-11-05 2021-12-07 安泰赛普生物风投二代有限责任公司 包含安非他酮或相关化合物和右美沙芬的组合物和方法
US9763932B2 (en) * 2013-11-05 2017-09-19 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10898453B2 (en) * 2013-11-05 2021-01-26 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US20200215059A1 (en) * 2013-11-05 2020-07-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20210052521A1 (en) * 2013-11-05 2021-02-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20210077428A1 (en) * 2013-11-05 2021-03-18 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021202419A1 *

Also Published As

Publication number Publication date
JP2023519965A (ja) 2023-05-15
CA3179048A1 (en) 2021-10-07
EP4125837A1 (de) 2023-02-08
WO2021202419A1 (en) 2021-10-07
JP2025032232A (ja) 2025-03-11
JP7637150B2 (ja) 2025-02-27
KR20220161414A (ko) 2022-12-06
CN115697314A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
EP4125837A4 (de) Verwendung von bupropion- und dextromethorphan-kombinationen zur behandlung von neurologischen erkrankungen
EP4226924A4 (de) Verwendung von penhyclidin zur behandlung oder prävention von sehbehinderten augenerkrankungen
EP3900717C0 (de) Vidofludimus zur verwendung in der behandlung oder prävention von viruserkrankungen
EP3959213C0 (de) Pyrimidin-jak inhibitoren zur behandlung von hauterkrankungen
EP4165025A4 (de) Zusammensetzungen und verfahren zur behandlung und prävention von neurologischen erkrankungen
EP4122474A4 (de) Verwendung von mitochondrien zur behandlung und/oder prävention von sehnenschäden oder verwandten erkrankungen
EP4117659A4 (de) Verfahren zur behandlung von atemwegserkrankungen mit deupirifenidon
EP4248212A4 (de) Verfahren zur behandlung von krankheiten und störungen
EP4352231A4 (de) Behandlung von angptl4-bedingten erkrankungen
EP4188410A4 (de) Chimäre proteine und verfahren zur verwendung zur behandlung von erkrankungen des zentralen nervensystems
EP4419504A4 (de) Kdm1a-hemmer zur behandlung von krankheiten
EP4447973A4 (de) Verwendung einer kombinationstherapie zur behandlung von krebs
EP4416176A4 (de) Behandlung von ige-vermittelten erkrankungen
EP4370153A4 (de) Verfahren zur behandlung neurologischer erkrankungen
EP4153168A4 (de) Verwendung von terpenoiden zur behandlung oder prävention fibrotischer erkrankungen
EP4210755A4 (de) Zusammensetzungen und verfahren zur behandlung von neurologischen erkrankungen
EP4216962A4 (de) Line-1-inhibitoren zur behandlung von krankheiten
EP4398908A4 (de) Behandlung von neurologischen erkrankungen
EP4410296A4 (de) Direkte transdifferenzierung zur behandlung von neurologischen erkrankungen
EP4338267A4 (de) Varianten von sirt6 zur verwendung bei der vorbeugung und/oder behandlung altersbedingter erkrankungen
EP4413032A4 (de) Behandlung von mastzellenbedingten erkrankungen
EP4237447A4 (de) Verwendung eines anti-cd19-antikörpers zur behandlung von autoimmunerkrankungen
EP4426276A4 (de) Verwendungen von rhodochinon zur behandlung von krankheiten
EP4363056A4 (de) Verwendung von terpenoiden zur behandlung oder prävention fibrotischer erkrankungen
EP4415737A4 (de) Zusammensetzungen und verfahren zur behandlung von hauterkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221028

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230509

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082817

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240220

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/34 20060101ALI20240214BHEP

Ipc: A61P 25/24 20060101ALI20240214BHEP

Ipc: A61K 31/485 20060101ALI20240214BHEP

Ipc: A61K 31/137 20060101AFI20240214BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250226

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TABUTEAU, HERRIOT